Isavuconazole
- PDF / 169,557 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 7 Downloads / 148 Views
1 S
Various toxicities: 8 case reports In a single-center and retrospective study involving 50 patients with haematologic malignancy, who received isavuconazole treatment between December 2015 and September 2017, 8 patients [ages and sexes not stated] were described, who developed increase in alanine aminotransferase (ALT), increase in aspartate aminotransferase (AST), increase in total bilirubin, hyperbilirubinaemia, purpuric skin nodules, squamous cell carcinoma or myalgia during treatment with isavuconazole [routes and outcomes not stated; not all durations of treatments to reactions onsets stated]. The patients, who were diagnosed with unspecified haematologic malignancy, started receiving isavuconazole 372 mg/day. However, four of the 8 patients developed transaminitis, manifesting as grade 3 increase in ALT after 6 months on isavuconazole (n=1), grade 3 increases in ALT and AST after 12 months on isavuconazole (n=1), grade 3 increases in ALT and total bilirubin after 6 months on isavuconazole (n=1) or grade 3 hyperbilirubinemia after 3 months on isavuconazole (n=1). Of the remaining 4 patients, 1 patient developed squamous cell carcinoma after more than 12 months of isavuconazole treatment, one patient developed squamous cell carcinoma within 3 months of initiation of isavuconazole, one patient developed purpuric skin nodules and one patient developed persistent myalgias following more than 12 months of isavuconazole treatment. DiPippo AJ, et al. Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy. Clinical Infectious Diseases 69: 1624-1627, No. 9, 15 Oct 803506737 2019. Available from: URL: http://doi.org/10.1093/cid/ciz159
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
